By Fineline Cube 
On August 21, 2025, Nanjing Zenshine Pharmaceuticals Co., Ltd, a China-based developer of small molecule drugs, announced a strategic cooperation agreement with Cigalah Medpharm Trading LLC, a leading pharmaceutical distributor in the MENA region. This partnership aims to advance the registration and commercialization of Zenshine’s self-developed anti-influenza drug, sebaloxavir marboxil, across eleven countries in the Middle East and North Africa.
Sebaloxavir Marboxil: A Breakthrough in Influenza Treatment
Sebaloxavir marboxil is an oral anti-influenza medication that offers high efficacy and safety with a convenient single-dose treatment regimen. The drug has already received marketing approval in China, demonstrating its strong clinical value. Its ability to provide a complete course of treatment with just one dose positions it as a highly attractive option for patients seeking effective and user-friendly influenza care.
About the Partners
- Nanjing Zenshine Pharmaceuticals Co., Ltd: A Chinese pharmaceutical company specializing in the development of innovative small molecule drugs, committed to addressing significant unmet medical needs.
- Cigalah Medpharm Trading LLC: A prominent diversified healthcare and pharmaceutical group in the MENA region, with extensive operations in manufacturing, distribution, retail, and medical services.-Fineline Info & Tech